The Codexis Pharma Services business unit has partnerships with these leading companies:
In 2004, Codexis entered into a multi-year, non-exclusive, broad-based collaboration focused on process research and development for some of Pfizer’s small molecule pharmaceutical products.
In 2006, Codexis announced a research agreement to develop a novel synthetic process for use by Schering-Plough focused on improving biocatalyst productivity.
In 2007, Codexis announced a technology collaboration in which Merck became the first subscriber to the Codex™ Biocatalyst Panels, a next-generation biotechnology research product.